On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Hervé Bonnefoi

ResearcherPublications, citations & collaboration network

Hervé Bonnefoi is a researcher indexed in ScholarIQ from OpenAlex & ORCID.

How many works does Hervé Bonnefoi have?

ScholarIQindexed works

Hervé Bonnefoi has 302 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Hervé Bonnefoi have?

ScholarIQcitation count

Hervé Bonnefoi has 25,150 citations in the OpenAlex counts ScholarIQ stores.

What is the h-index of Hervé Bonnefoi?

ScholarIQh-index

Hervé Bonnefoi has an h-index of 55 in OpenAlex.

What is the i10-index of Hervé Bonnefoi?

ScholarIQi10-index

Hervé Bonnefoi has an i10-index of 134 in OpenAlex.

What is the ORCID of Hervé Bonnefoi?

ScholarIQorcid

The ORCID for Hervé Bonnefoi is on the source record.

What is the OpenAlex record for Hervé Bonnefoi?

ScholarIQopenalex

The OpenAlex for Hervé Bonnefoi is on the source record.

What are the most-cited papers on Hervé Bonnefoi?

ScholarIQmost cited works
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P. Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa, Sandra M. Swain, Tatiana M. Prowell, Sibylle Loibl, D. Lawrence Wickerham, Jan Bogaerts, José Baselga, Charles M. Perou, Gideon M. Blumenthal, Jens‐Uwe Blohmer, Eleftherios P. Mamounas, Jonas Bergh, Semiglazov Vf, Robert Justice, Holger Eidtmann, Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter A. Fasching, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles E. Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, W. Eiermann, Gϋnter von Minckwitz
The Lancet. 20144,765 CitationsOPEN ACCESS
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Aron Goldhirsch, Eric P. Winer, Alan S. Coates, Richard D. Gelber, Martine Piccart, Beat Thürlimann, Hans-Jörg Senn, Kathy S. Albain, Fabrice André, Jonas Bergh, Hervé Bonnefoi, Denisse Bretel-Morales, Harold J. Burstein, Fátima Cardoso, Monica Castiglione‐Gertsch, Alan S. Coates, Marco Colleoni, Alberto Costa, Giuseppe Curigliano, Nancy E. Davidson, Angelo Di Leo, Bent Ejlertsen, John Forbes, Richard D. Gelber, Michael Gnant, Aron Goldhirsch, Pamela J. Goodwin, Paul E. Goss, Jay R. Harris, Daniel F. Hayes, Clifford A. Hudis, James N. Ingle, Jacek Jassem, Zefei Jiang, Per Karlsson, Sibylle Loibl, Monica Morrow, Moïse Namer, C. Kent Osborne, Ann H. Partridge, Frédérique Penault‐Llorca, Charles M. Perou, Martine Piccart, Kathleen I. Pritchard, Emiel J. Rutgers, Felix Sedlmayer, Semiglazov Vf, Zhi‐Ming Shao, Ian Smith, Beat Thürlimann, Masakazu Toi, Andrew Tutt, Michael Untch, Giuseppe Viale, Toru Watanabe, Nicholas Wilcken, Eric P. Winer, William C. Wood
Annals of Oncology. 20133,743 CitationsOPEN ACCESS
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Giuseppe Curigliano, Harold J. Burstein, Eric P. Winer, Michael Gnant, Peter Dubsky, Sibylle Loibl, Marco Colleoni, Meredith M. Regan, Martine Piccart, Hans-Jörg Senn, Beat Thürlimann, Fabrice André, José Baselga, Jonas Bergh, Hervé Bonnefoi, Sara Y. Brucker, Fátima Cardoso, Lisa A. Carey, Eva Ciruelos, Jack Cuzick, Carsten Denkert, Angelo Di Leo, Bent Ejlertsen, Prudence A. Francis, V.E. Galimberti, Judy E. Garber, Bahadır M. Güllüoğlu, Pamela J. Goodwin, Nadia Harbeck, Daniel F. Hayes, Chiun‐Sheng Huang, Jens Huober, Hussein Khaled, Jacek Jassem, Zefei Jiang, Per Karlsson, Monica Morrow, Roberto Orecchia, Kent C. Osborne, Olivia Pagani, Ann H. Partridge, K. Pritchard, Jungsil Ro, Emiel J. Rutgers, Felix Sedlmayer, Semiglazov Vf, Zhi‐Ming Shao, Ian Smith, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Toru Watanabe, Timothy J. Whelan, Binghe Xu
Annals of Oncology. 20171,258 CitationsOPEN ACCESS
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
Sherene Loi, Anita Giobbie‐Hurder, Andrea Gombos, Thomas Bachelot, Rina Hui, Giuseppe Curigliano, Mario Campone, Laura Biganzoli, Hervé Bonnefoi, Guy Jérusalem, Rupert Bartsch, Manuela Rabaglio, Roswitha Kammler, Rudolf Maibach, Mark J. Smyth, Angelo Di Leo, Marco Colleoni, Giuseppe Viale, Meredith M. Regan, Fabrice André, Debora Fumagalli, Richard D. Gelber, Theodora Goulioti, Anita Hiltbrunner, Rita L. Hui, Heidi Roschitzki, Barbara Ruepp, Frances M. Boyle, Rolf A. Stahel, Stefan Aebi, Alan S. Coates, Aron Goldhirsch, Per Karlsson, Ingrid Kössler, Stamatina Fournarakou, Adriana Gasca, Rita Pfister, Sabrina Ribeli-Hofmann, Magdelena Weber, Daniela Celotto, Carmen Comune, M. Frapolli, Magdalena Sánchez-Hohl, Hui Huang, Caitlin Mahoney, Karen N. Price, Karolyn Scott, Holly Shaw, Susan M. Fischer, Mónica Greco, Colleen King, Stefania Andrighetto, Martine Piccart, Heather E. Findlay, Michelle Jenkins, Vassiliki Karantza, Jaime Mejia, Patrick Schneier
The Lancet Oncology. 2019481 Citations

Related on ScholarIQ

470M+ articles · free account